Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
forget about it
EDIT: negative volume continues.................
Trend divergence is evident in volume studies in lesser duration and greatest duration charts. The market for DNAP has not been as price indicates. If any good technical news can be found here it would be the "harami" printing today at support. Confirmed trend divergence is quite supportive of shennanigans ongoing in overall volume. A convincing break of todays low or .012 probably lends logic for near term direction to at least .008 or .015. Nonetheless, confirmed mathematics strongly suggest the market is being fooled. The gold box highlights the period where Dutchess began involvement. Note the volume increase.
you prove my points well
bag.........................
I can use the word "pig" in describing the DNAP stock and be threatened by several people here and matt warning to do whatever he thinks he does. Yet you and your friends can say anything you like without recourse from any management of these boards. Quite petty of you, ya think? Cheap shots are plenty. It must be what all of you are good at.
Do you know what it's like to attempt taking a breath and and your body fails to respond? You find that humourous, it seems.
I will have the last laugh - breathing or not. DNAP is a fraud. .0001 is coming. You've been warned.
silica poisoning. you should try it. they have forecasted my demise for years. nothing will change .0001 from coming. use the coming opportunity to exit. you have been warned. .0001 is coming.
investo.........................
.
.
easymedicine@lycos.com
gunna...... you'll see.
dear team.......................
.
Everyone was new at investing at one time. You'll catch on. Watch the guy hiding behind the curtain. He thinks you are pretty. Volume ain't what you think.
hey pumpers.......................
.
Got out of the hospital today. Stupid lungs. You need me to stay longer, huh? Now that I'm home I'll have to bash harder. (LOL) You guys are a hoot.
The chart is suggesting a new relative high Monday with a retrace coming thereafter. Negative volume continues - systematic shorts and/or new shares ongoing. .0001 is coming. You've been warned.
UVCL..............................
.
LMMG..............................
.
Got home from the hospital today. Feelin' okay.
That Tiger fella is somethin' else, ain't he?
team.............................
Wanna see how those financial deals work out into the math of your investment? These are old ones. Imagine what a new share release of 1.5 billion shares will do! .0001 is coming.
Basic net loss per share is computed by dividing the net loss available to
common stockholders by the weighted average number of common shares outstanding
during the period. Diluted net loss per share is computed by dividing the net
loss for the period by the weighted average number of common and common
equivalent shares outstanding during the period. Common equivalent shares
outstanding as of December 31, 2004 and 2003, which consist of employee stock
options, warrants, convertible debenture as well as the issuance of common stock
under compensation agreements, have been excluded from diluted net loss per
common share calculations because they are anti-dilutive. Accordingly, basic and
diluted net loss per share is identical as of December 31, 2004 and 2003 and for
the period December 10, 1998 to December 31, 2004. The following table
summarizes our common stock equivalents outstanding at December 31, 2004 which
may dilute future earning per share.
Convertible notes ** 338,723,034
Convertible preferred stock ** 44,943,820
Warrants and options 26,650,308
--------------
410,217,162
==============
**The amount of shares the convertible notes and convertible preferred
stock was estimated using the conversion price at December 31, 2004.
The conversion price varies based upon the price of our common stock
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094
another fine decision from the underwear drawer management team of DNAP:
Advertising costs, which approximated $24,585 and $2,075, respectively, for the
years ended December 31, 2004 and 2003, are expensed as they are incurred.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094
Common stock issuances (2004):
Via 506 Private Placement
at $.05 per share 14,324,000
For consulting services
at $.05 per share 800,000
Through funding agreement
with TBFI at $.05 per share 7,816,620
From exercise of
nonqualified stock
options at $.05 per
share 11,250,000
For bankruptcy settlements
at $.02 per share 10,695,768
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094
Stock options? Like in puts they subscribe to help fund operations per last Q report? Another breakdown:
Common stock issuances:
For settlement of related party notes payable and interest
at $0.032 17,307,983
For settlement of related party notes payable and interest
at $0.032 8,067,238
For settlement of related party notes payable and interest
at $0.074 2,710,043
For settlement of related party notes payable and interest
at $0.072 8,092,592
For consulting services at $.030 per share 2,780,867
For consulting services at $.048 per share 333,725
For consulting and scientific advisory board services
at $.073 per share 269,937
For scientific advisory board services at $.048 per share 100,000
For accounting services at $.026 per share 84,150
For legal services at $.068 per share 58,330
For legal services at $.077 per share 70,778
Each time they issue new stock, your invested dollar becomes less and less. They are pretty free with your money, huh?
bigdrive.....................
I brought up this math problem weeks ago. And in being conservative DNAP would have to sell 1.5 billion new shares at around .007 (if I remember correctly) to net $10 million. So anyone can see, DNAP lies again. They must believe everyone is stupid. 10 million is nowhere near the 35 million they said they wanted.
All this company does is lie about their intentions and what they do.
you are such a nice boy - good night eom
i base opinion from experience and the financial records reported by DNAP themselves. .0001 is coming
something in burlapor paper, perhaps? appropriate for DNAP proceeds (if any)
altar..........................
Selective vision by doug and matt and the immaturity of many posters herein have promoted my increasing presence. Enjoy.
The accompanying consolidated financial statements of DNAPrint genomics, Inc.
and Subsidiary have been prepared assuming that the Company will continue as a
going concern. As more fully described in Note B, the Company has had recurring
operating losses since inception, has negative working capital as of December
31, 2004, and has used approximately $3,764,000 of cash in operations for the
year ended December 31, 2004. These conditions raise substantial doubt about the
Company's ability to continue as a going concern. Management's plans regarding
these matters are also described in Note B. The consolidated financial
statements do not include any adjustments that might result from the outcome of
this uncertainty.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094
Based upon our current plans, we will continue to focus on increasing market
awareness of our products and developing sales for our currently available
consumer and forensic products and to begin introductory marketing for our new
products, EUROWitness(TM), RETINOME(TM) and EURO- DNA(TM). Our efforts are
ongoing; however, it is difficult to predict what revenue stream, if any, they
will generate.
THIS ONE IS TOO FUNNY - A COMPANY THAT HAS NOTHING, IS WORTH NOTHING, INTENDS TO BUY INTO A COMPANY THAT MAY BE WORTH SOMETHING AND HAS MARGINAL, IF ANY, INTRINSIC/EXTRINSIC VALUE. NOTE THE PRETENSE TOO. ORIGINAL FINANCING WAS NOT EXHAUSTED, BUT CONTINUES UNDER NEW PRETENSES. IS THIS THEFT AND DECEPTION OR WHAT????????
Although the Biofrontera acquisition was terminated, the Company expects to use
its $35 million dollar funding facility with Dutchess Equity Partners because of
its previously stated goals and objectives to grow the business. The Company is
currently seeking acquisition candidates that will meet criteria set out by the
Board of Directors of the Company that include but are not limited to:
1. Positive Cash Flow
2. Profitable Operations
3. Market Recognition
4. Talented and Dedicated Staff
5. Complimentary Certifications that can include: American
Society of Forensic Laboratory Directors, American Blood Bank
Certification or Clinical Laboratory Certification or other
complementary certifications that will help the Company expand
its products, services and research and development into
consumer, forensics and pharmaceutical applications.
In order to complete future acquisitions and to provide working capital for us,
on September 28, 2004, we entered into an Investment Agreement and a
Registration Rights Agreement with Dutchess Private Equities Fund, II, L.P.,
("Dutchess", or the "Investor") a Delaware limited partnership. The agreement
will require us to register a sufficient number of shares that we will then
issue to Dutchess in return for up to $35 million in cash over a two-year
period. The Company will be required to seek additional shareholder approval for
a restructuring of the capital stock of the Company in order to use fully the
Dutchess facility in order to continue operations and complete acquisitions.
We evaluated a number of other investment vehicles, including private placement
through venture capital sources and concluded that not only were the terms and
conditions prohibitive to our Company but they also brought high equity
dilution. The Dutchess Agreement provided the lowest dilution (dependent upon
our share price) with the fewest restrictions.
The Dutchess Agreement provides that we from time to time may deliver a notice
to the Investor that will state the dollar amount of common stock that we desire
the Investor to purchase. The maximum amount permitted pursuant to any such
notice is $600,000, and we can give approximately three such notices per month.
Upon receipt of the notice, the Investor is obliged to purchase the dollar
amount of common stock set forth in the notice at a purchase price equal to 96%
of the average of the two lowest closing bid prices of the common stock during
the five trading days after the notice.
The obligation of the Investor to purchase under the Dutchess Agreement is
contingent upon our filing and having declared effective a registration
statement registering the resale of the shares by the Investor. Simultaneously,
the parties entered into a Registration Rights Agreement requiring us to file
such a registration statement. In addition, we are not permitted to provide a
notice, and the Investor is not obliged to purchase any shares, in the event
that we do not have sufficient authorized shares available for purchase to
fulfill such commitment.
We do not expect our revenue stream to be sufficient to cover costs of
operations in the immediate future. We anticipate that the funding we expect to
receive from the minimum conversions of the outstanding debenture into common
stock, the related exercise of the non-detachable warrants and the Dutchess
agreement will fund our operating activities through 2005. The Dutchess
agreement that we recently negotiated will provide up to $35 million in
additional cash over a 24-month period to fund future acquisitions, if any, and
provide operating cash flow. If our share price continues to remain weak; if our
shareholders' do not approve an increase in capitalization when required; if the
SEC S-2 registration is not completed, and if any number of adverse factors or
events occur, we will not have enough equity to complete future acquisitions or
possibly to continue operations beyond 2005. Management is adequately confident
that equity financing or debt will be available to fund our operations until
revenue streams are sufficient to fund operations; however, the terms and timing
of such equity or debt cannot be predicted.
We have issued securities, including our convertible debentures and our
convertible preferred stock, that are convertible into our common stock at a
continuously adjustable conversion price based on a discount on the trading
price of our common stock. In addition, our Investment Agreement with Dutchess
requires us, in order to raise capital from it, to sell our common stock to it
at a continuously adjustable conversion price at a discount to the trading price
of our common stock. As we draw down advances under the Investment Agreement
with Dutchess and more of our common stock is sold pursuant thereto, the market
price of our common stock could decrease significantly and make further advances
impractical or impossible during time periods in which we may need to raise
capital to fund our operations and market and sell our products and services. In
addition, the issuance of our common stock upon exercise or conversion of our
other securities, may create a downward pressure on the market price of our
common stock.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094
I look at DNAP and see fraud, theft, and deception.
DNAP is a self-proclaimed "industry leader". all they need now is someone to believe them and something to sell that is worth selling.
DNAP needs people like you who believe anything they could make up. Did you buy any more shares after that Harvard bs? They'll love ya for it.
hey gunna..........................
How much did they soak you for this time? The charts were right again, huh? Can't fool them too often.
How 'bout that Harvard news? A lot about nothin' it seems. I netted 34% on my last DNAP trade. How much are you down?
all you need is good management and something to sell, huh? yer on a roll!!!!!!!!!!!
traders nation gets paid in new shares of DNAP for the touting of the worthless stock. you thump your chest for this silly crap? you are hilarious!
Did you note how the pay for recognition guys are touting DNAP? That's hilarious. I played golf yesterday. DNAP is much too risky now with shorts and convertibles suckering you guys into the next big share price dip. .0001 is coming. Count on it.
I netted 34% on my last DNAP trade. How much are you down?
DNAP repeatedly refers to questionable survival...........
in the last K. They refer to the share price being reflective of the insurmountable trouble they have. They openly admit they have no assets and all viable technology is fully exploited. DNAP confesses no one of reputable dealings will ever loan them cash. They question their own future and managerial skills. All of this can be found in the K. http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094
negative volume in lesser duration charts...........
massive systematic shorting or share conversions are underway in DNAP
i played golf today. it was fun. it will be fun seeing you lose all your money too. .0001 is coming
i netted 34% on my last DNAP trade. how much are you down?
Negative volume??????????????????
In a perfect world when things are as they should be, volume studies mirror price in all relativity. In DNAP they do not. Look at time and sales reports today. Oddities galore! Someone is converting/flipping volume. It even shows in the chart. You are being stole from and you thump your chests with pride while they do it. Too funny. (LOL)
they are converting!!!!!! better get out quick before the show stops
yep..... scam. where are dates? where are hard numbers? where are anything concrete coming from the news? they cannot be found. it means nothing. look at time and sales today. see anything preculiar? (LOL) You have absolutely no idea what is going on. enjoy your loss.
vague and ambiguous otc scam news. look for new shares being dumped
you and your peers call me names, insult me because you cannot adequately defend the thieves of DNAP. Yet I refer to the stock as a "pig" and get bounced?????????? I should take no offense from anything you say or do? I will make it a point from here on to identify the lies and theft DNAP performs on a daily basis. Thank you.
panic? no. just pointing out some.........
interesting truths, like always. selective vision by management here may have encouraged a bit of vigor. but I know this company is nothing. they lie. they steal. you and your peers here are victims, and perhaps participants. enjoy your demise. you should get a little something for your money lost.
how could I be a basher when all I do...........
is offer truths you and your peers seemingly prefer to overlook? Here, DNAP confesses they do not incorporate cost accounting in their management. That's a complete disaster waiting to happen, huh? I guess that's another element considered in the share price. But yet, they know of some costs. I think that odd how only a few costs are evident while others totally escape the picture. "we
began recording inventory since during the last half of 2004" just began recording inventory??????????? These guys are thieves or idiots.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094
While we continue to improve and refine our accounting systems, we currently do
not segregate product costs by product or service. At December 31, 2004, we
began recording inventory since during the last half of 2004, we were increasing
the amount of raw materials we have on hand. We have been and continue to be a
development stage company as described in Financial Accounting Standards Board
Statement No. 7. We continue to devote substantially all of our efforts to
initiating and developing our planned principal operations. We expect that our
pharmacogenomic products and services, once introduced, will be our major
revenue generator.
Management does not manage on a product cost basis at this time. Further,
management does not allocate resources based on product lines. For the most
part, personnel are not solely devoted to a product or a specific task. As a
development stage company, personnel are required to perform a multitude of
tasks including production and research and development. Revenue generation to
date has not been substantial or steady enough to warrant segregation of duties.
As such, labor costs vary from period to period. Further, we have not reached a
stage where economies of scale are available to us. Production costs vary from
period to period due to the level of revenue produced and research performed. We
anticipate, as stated previously, that as we move from a development stage
company to an operating company, management will focus on product revenues,
costs and the associated margins. As part of our effort to become an operating
company, we continue to develop and refine our production processes for our
introduced products; so that over time and as sales increase, an efficient
process can be implemented and managed on an ongoing basis. In addition, we
continue to work towards designing and establishing a cohesive marketing and
sales effort for our introduced products. Although both the forensic and
genealogy markets have been in existence for several years, our products are new
and unique to their markets, and it requires market research and testing in
order to arrive at the best way to present our products. We continue to test
markets through primary market research and advertising. This effort is ongoing
and will continue to develop as we gather information.
Cost of sales increased from $432,224 (61% of revenues) in 2003 to $507,927 (65%
of revenues) in 2004. The increase in cost of sales as a percent of revenues is
due to our refinement of our estimate and allocation of research and development
costs. Because of our small sales volume, these results are not indicative of
the margins that we expect to attain if our long-term goals are achieved. We
anticipate that as we gain experience and can begin to take advantage of
economies of scale benefits through increased revenues and our margins will
stabilize and begin to track in line with other companies in similar industries.
However, in the near term, while we continue to be a development stage
enterprise, we expect that our margins will continue to fluctuate.
Our independent auditors have expressed doubt about our ability to continue as a
going concern, which may hinder our ability to obtain future financing.
In their report dated February 25, 2005, our independent registered public
accounting firm has expressed doubt about our ability to continue as a going
concern in our financial statements for the year ended December 31, 2004 and
2003. Our ability to continue as a going concern is an issue raised as a result
of recurring losses from operations, a working capital deficit, and requirement
for a significant amount of capital financing to proceed with our business plan.
Our ability to continue as a going concern is subject to our ability to generate
a profit and/or obtain necessary funding from outside sources, including
obtaining additional funding from the sale of our securities, increasing sales
or obtaining loans and grants from various financial institutions where
possible.
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=3370094
what are you going to do if share price...............
briefly goes up, goes flat, or continues downward? you know in your heart that is what will happen.
this pr affords no dates, no hard.............
numbers, nothing concrete. It is a typical otc scam pr.
if DNAP had anything at all, revenues............
would be present demonstrating such existed - plain and simple. DNAP has absolutely nothing. Never did, never will. They are in business to sell new shares, nothing else.